News

JLL Income Property Trust Plans Q3 Earnings Call for Investors

JLL Income Property Trust Plans Q3 Earnings Call for Investors

Upcoming Q3 Earnings Call by JLL Income Property Trust

JLL Income Property Trust has exciting news for its investors! They will hold a public earnings call to discuss the financial performance for the third quarter. This institutionally managed daily NAV REIT operates under NASDAQ ticker symbols ZIPTAX, ZIPTMX, ZIPIAX, and ZIPIMX, managing a substantial portfolio valued at around $6.6 billion.

Details of the Earnings Call

The earnings call is scheduled for November 13, 2024, at 9:00 AM CT. Investors and stakeholders are encouraged to join this session as the team presents an in-depth overview of recent economic trends and their implications on property investments. Chief Financial Officer Gregg Falk and Portfolio Manager Lucas Kimmel will be leading the presentation. They will provide insights into the financial results of the quarter, recent accomplishments, and market influences affecting their portfolio.

How to Participate in the Call

To join the call, participants can dial the toll-free number 888-506-0062. For those calling from international locations, the number is 973-528-0011. An access code will be required for entry; insiders can use code 394974 for direct access.

Accessing the Replay of the Call

In case you miss the live session, don't worry! The replay will be available until November 20, 2024, at 9:00 AM CT. To access the replay, use the toll-free number 877-481-4010, or for international callers, use 919-882-2331. Remember, the replay passcode is 50003.

About JLL Income Property Trust

JLL Income Property Trust offers investors access to a carefully curated collection of high-quality real estate investments. Managed by an experienced team, they focus on core assets across various sectors—including residential, healthcare, and retail properties—located primarily across the United States. This commitment to quality and diversification is reflected in their growth strategy, ensuring a balanced real estate portfolio.

Looking Ahead

As JLL Income Property Trust continues to navigate the dynamic real estate landscape, their focus remains on optimizing returns for investors. Their strategic planning includes expanding their investment portfolio, with potential global diversification in the mix. Investors are encouraged to stay informed and participate actively in the upcoming earnings call to gain deeper insights into their operations and future plans.

Contacts for Further Information

Should you have any inquiries or need additional details, please feel free to reach out to the following dedicated contacts:

Alissa Schachter
LaSalle Investment Management
Telephone: +1 312 339 0625
Email: Alissa.schachter@lasalle.com

Doug Allen
Dukas Linden Public Relations
Telephone: +1 646 722 6530
Email: JLLIPT@DLPR.com

Frequently Asked Questions

What is the date and time of the Q3 earnings call?

The Q3 earnings call is scheduled for November 13, 2024, at 9:00 AM CT.

How can I participate in the earnings call?

Participants can dial 888-506-0062 for the toll-free line or 973-528-0011 for international calls. An access code is required.

Will there be a replay available for the earnings call?

Yes, the replay will be available until November 20, 2024, at 9:00 AM CT.

What types of properties does JLL Income Property Trust manage?

They manage a diverse portfolio, including residential, healthcare, industrial, and retail properties.

Who are the key people presenting during the call?

Gregg Falk, Chief Financial Officer, and Lucas Kimmel, Portfolio Manager, will present during the call.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 170

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 336

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 372

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 64

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Trump's Executive Orders and Their Economic Impact

Updated Category News Views 806

Executive Orders: A Shift in Economic Paradigms President Trump has taken significant steps by issuing a number of executive orders that have raised eyebrows among economists and market analysts alike. According to market expert Louis Navellier, this approach can be characterized as 'shock and awe'. It reflects a bold strategy that could reshape various aspects of the...

Continue Reading
B2PRIME Expands Institutional Reach with Stuart Brock's Addition

Updated Category News Views 173

B2PRIME Welcomes Stuart Brock as Institutional Business Development Manager B2PRIME Group, a leading financial services provider for institutional and professional clients, recently announced the appointment of Stuart Brock as its Institutional Business Development Manager. With over 15 years of experience in electronic trading and institutional sales, Stuart is poised to...

Continue Reading
United Parks & Resorts Inc. Shares Q1 2025 Financial Insights

Updated Category News Views 374

Financial Overview of United Parks & Resorts Inc. United Parks & Resorts Inc. (NYSE: PRKS), a prominent player in the theme park and entertainment sector, has recently shared its financial results for the first quarter of 2025. This report delves into the key metrics and operational insights that define the company’s performance in this period. Attendance and Revenue...

Continue Reading
Seongnam Pavilion Sets New Benchmark at CES 2025 with 41 Companies

Updated Category News Views 178

Seongnam Pavilion Makes Waves at CES 2025 At the latest CES 2025, Seongnam City showcased an impressive turnout at the world's leading consumer electronics exhibition. This year, Seongnam participated with a remarkable delegation of 41 companies, marking the largest participation ever. Focused on enhancing their global footprint, these small and medium-sized enterprises...

Continue Reading
Gaucho Holdings Seizes Opportunities Amid Argentina's Economic Revival

Updated Category News Views 179

Gaucho Holdings and the New Economic Landscape in Argentina Recently, Argentina has entered a new chapter of economic transformation. A shift in leadership, with Javier Milei becoming president, has sparked hopes for fiscal discipline, growth, and development. As the country embraces pro-market reforms, Gaucho Group Holdings, Inc. (NASDAQ: VINO) positions itself to...

Continue Reading